BACKGROUND: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC).
METHODS: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed.
RESULTS: In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18% higher risk of time-to-treatment failure (TTF), and a 39% higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46% decreased risk of TTF and 62% decreased risk of death.
CONCLUSIONS: mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with first-line SU showed a better outcome compared with SO.
Written by:
Grassi P, Verzoni E, Porcu L, Iacovelli R, de Braud F, Procopio G. Are you the author?
Medical Oncology 1, Fondazione IRCCS, Istituto Nazionale Tumori, Via G. Venezian 1, Milan, Italy; Medical Oncology 1, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy; Laboratory of Methodology for Biomedical Research, Oncology Department, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
Reference: Ther Adv Urol. 2015 Apr;7(2):59-68.
doi: 10.1177/1756287215571809
PubMed Abstract
PMID: 25829949